Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Triple-negative breast cancers have inherent defects in DNA repair, making this cancer a rational target for therapy based on poly(adenosine diphosphate-ribose) polymerase (PARP) inhibition. METHODS: We conducted an open-label, phase 2 study to compare the efficacy and safety of gemcitabine and carboplatin with or without iniparib, a small molecule with PARP-inhibitory activity, in patients with metastatic triple-negative breast cancer. A total of 123 patients were randomly assigned to receive gemcitabine (1000 mg per square meter of body-surface area) and carboplatin (at a dose equivalent to an area under the concentration-time curve of 2) on days 1 and 8--with or without iniparib (at a dose of 5.6 mg per kilogram of body weight) on days 1, 4, 8, and 11--every 21 days. Primary end points were the rate of clinical benefit (i.e., the rate of objective response [complete or partial response] plus the rate of stable disease for ≥6 months) and safety. Additional end points included the rate of objective response, progression-free survival, and overall survival. RESULTS: The addition of iniparib to gemcitabine and carboplatin improved the rate of clinical benefit from 34% to 56% (P=0.01) and the rate of overall response from 32% to 52% (P=0.02). The addition of iniparib also prolonged the median progression-free survival from 3.6 months to 5.9 months (hazard ratio for progression, 0.59; P=0.01) and the median overall survival from 7.7 months to 12.3 months (hazard ratio for death, 0.57; P=0.01). The most frequent grade 3 or 4 adverse events in either treatment group included neutropenia, thrombocytopenia, anemia, fatigue or asthenia, leukopenia, and increased alanine aminotransferase level. No significant difference was seen between the two groups in the rate of adverse events. CONCLUSIONS: The addition of iniparib to chemotherapy improved the clinical benefit and survival of patients with metastatic triple-negative breast cancer without significantly increased toxic effects. On the basis of these results, a phase 3 trial adequately powered to evaluate overall survival and progression-free survival is being conducted. (Funded by BiPar Sciences [now owned by Sanofi-Aventis]; ClinicalTrials.gov number, NCT00540358.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The oncology literature has indicated that positive phase II data are not necessarily replicated in the phase III setting”
In the citing paper
“Furthermore, ongoing clinical trials for metastatic TNBC are including platinum agents in their treatment regimens (4, 36–38).”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [36]
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., McFadden, E. T., & Carbone, P. P. (1982) · AMERICAN JOURNAL OF CLINICAL ONCOLOGY · doi:10.1097/00000421-198212000-00014 · Cited by 11,647
Sørlie, T., Perou, C. M., Tibshirani, R., Aas, T., Geisler, S., Johnsen, H., Hastie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191367098 · Cited by 10,938
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Repeated observation of breast tumor subtypes in independent gene expression data sets
Sørlie, T., Tibshirani, R., Parker, J., Hastie, T., Marron, J. S., Nobel, A., Deng, S., Johnsen, H., Pesich, R., Geisler, S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0932692100 · Cited by 5,429
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Parker, J. S., Mullins, M., Cheang, M. C. U., Leung, S., Voduc, D., Vickery, T., Davies, S., Fauron, C., He, X., Hu, Z., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1370 · Cited by 4,721
Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study
Carey, L. A., Perou, C. M., Livasy, C. A., Dressler, L. G., Cowan, D., Conway, K., Karaca, G., Troester, M. A., Tse, C. K., Edmiston, S., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2492 · Cited by 3,819
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,891
Cited by
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981
The resurgence of covalent drugs
Singh, J., Petter, R. C., Baillie, T. A., & Whitty, A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3410 · Cited by 1,873
New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
Gibson, B. A., & Kraus, W. L. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3376 · Cited by 1,226
Gelmon, K. A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., Hirte, H., Huntsman, D., Clemons, M., Gilks, B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,117
Huang, R., & Zhou, P.-K. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00648-7 · Cited by 907
Voorwerk, L., Slagter, M., Horlings, H. M., Sikorska, K., van de Vijver, K. K., de Maaker, M., Nederlof, I., Kluin, R. J. C., Warren, S., Ong, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0432-4 · Cited by 905
Abkevich, V, Timms, K. M., Hennessy, B. T., Potter, J., Carey, M. S., Meyer, L. A., Smith-McCune, K., Broaddus, R., Lu, K. H., Chen, J., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.451 · Cited by 815
Opportunities and challenges of radiotherapy for treating cancer
Schaue, D., & McBride, W. H. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.120 · Cited by 784
An overview of triple-negative breast cancer
Kumar, P., & Aggarwal, R. (2016) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-015-3859-y · Cited by 771
Gucalp, A., Tolaney, S., Isakoff, S. J., Ingle, J. N., Liu, M. C., Carey, L. A., Blackwell, K., Rugo, H., Nabell, L., Forero, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3327 · Cited by 749
Molecular biology in breast cancer: Intrinsic subtypes and signaling pathways
Eroles, P., Bosch, A., Alejandro Pérez-Fidalgo, J., & Lluch, A. (2012) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.11.005 · Cited by 624
Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
Traina, T. A., Miller, K., Yardley, D. A., Eakle, J., Schwartzberg, L. S., O’Shaughnessy, J., Gradishar, W., Schmid, P., Winer, E., Kelly, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3495 · Cited by 530
Self-citationLehmann, B. D., & Pietenpol, J. A. (2014) · The Journal of Pathology · doi:10.1002/path.4280 · Cited by 495
Maeda, H., & Khatami, M. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-018-0185-6 · Cited by 491
Kim, S. M., Yang, Y., Oh, S. J., Hong, Y., Seo, M., & Jang, M. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.013 · Cited by 481
Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors
Lord, C. J., Tutt, A. N. J., & Ashworth, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-050913-022545 · Cited by 471
Dissecting the Heterogeneity of Triple-Negative Breast Cancer
Metzger-Filho, O., Tutt, A., de Azambuja, E., Saini, K. S., Viale, G., Loi, S., Bradbury, I., Bliss, J. M., Azim, H. A., Ellis, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.2010 · Cited by 465
Brenner, J. C., Ateeq, B., Li, Y., Yocum, A. K., Cao, Q., Asangani, I. A., Patel, S., Wang, X., Liang, H., Yu, J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.010 · Cited by 415
Basal Breast Cancer: A Complex and Deadly Molecular Subtype
Bertucci, F., Finetti, P., & Birnbaum, D. (2012) · Current Molecular Medicine · doi:10.2174/156652412798376134 · Cited by 394
The fate of chemoresistance in triple negative breast cancer (TNBC)
O’Reilly, E. A., Gubbins, L., Sharma, S., Tully, R., Guang, M. H. Z., Weiner-Gorzel, K., McCaffrey, J., Harrison, M., Furlong, F., Kell, M., et al. (2015) · BBA Clinical · doi:10.1016/j.bbacli.2015.03.003 · Cited by 377
An update on PARP inhibitors—moving to the adjuvant setting
Sonnenblick, A., de Azambuja, E., Azim, H. A., & Piccart, M. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.163 · Cited by 373
Targeted therapies for breast cancer
Higgins, M. J., & Baselga, J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci57152 · Cited by 369
Chen, Z., Liu, L., Liang, R., Luo, Z., He, H., Wu, Z., Tian, H., Zheng, M., Ma, Y., & Cai, L. (2018) · ACS Nano · doi:10.1021/acsnano.8b04371 · Cited by 363
Targeted therapies in breast cancer: New challenges to fight against resistance
Masoud, V., & Pagès, G. (2017) · World Journal of Clinical Oncology · doi:10.5306/wjco.v8.i2.120 · Cited by 357
Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies
Lee, A., & Djamgoz, M. B. A. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.003 · Cited by 354
Subtyping of triple‐negative breast cancer: Implications for therapy
Abramson, V. G., Lehmann, B. D., Ballinger, T. J., & Pietenpol, J. A. (2015) · Cancer · doi:10.1002/cncr.28914 · Cited by 333
Predictive biomarkers: a paradigm shift towards personalized cancer medicine
La Thangue, N. B., & Kerr, D. J. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.121 · Cited by 332
André, F., & Zielinski, C. C. (2012) · Annals of Oncology · doi:10.1093/annonc/mds195 · Cited by 329
The role of PARP in DNA repair and its therapeutic exploitation
Javle, M., & Curtin, N. J. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.382 · Cited by 320
New Strategies for Triple-Negative Breast Cancer—Deciphering the Heterogeneity
Mayer, I. A., Abramson, V. G., Lehmann, B. D., & Pietenpol, J. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0583 · Cited by 320
O'Shaughnessy, J., Schwartzberg, L., Danso, M. A., Miller, K. D., Rugo, H. S., Neubauer, M., Robert, N., Hellerstedt, B., Saleh, M., Richards, P., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.2984 · Cited by 311
Self-citationCurrent approaches to the treatment of metastatic brain tumours
Owonikoko, T. K., Arbiser, J., Zelnak, A., Shu, H.-K. G., Shim, H., Robin, A. M., Kalkanis, S. N., Whitsett, T. G., Salhia, B., Tran, N. L., et al. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.25 · Cited by 304
1st International consensus guidelines for advanced breast cancer (ABC 1)
Cardoso, F., Costa, A., Norton, L., Cameron, D., Cufer, T., Fallowfield, L., Francis, P., Gligorov, J., Kyriakides, S., Lin, N., et al. (2012) · The Breast · doi:10.1016/j.breast.2012.03.003 · Cited by 303
Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease
Kalimutho, M., Parsons, K., Mittal, D., López, J. A., Srihari, S., & Khanna, K. K. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.08.009 · Cited by 294
The intersection between DNA damage response and cell death pathways.
Nowsheen, S., & Yang, E. S.-H. (2012) · PubMed · Cited by 284
PARP-1 and gene regulation: Progress and puzzles
Kraus, W. L., & Hottiger, M. O. (2013) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2013.01.005 · Cited by 261
Lee, K.-L., Kuo, Y.-C., Ho, Y.-S., & Huang, Y.-H. (2019) · Cancers · doi:10.3390/cancers11091334 · Cited by 260
Triple-negative breast cancer: recent treatment advances
Bergin, A. R. T., & Loi, S. (2019) · F1000Research · doi:10.12688/f1000research.18888.1 · Cited by 248
Oncogene addiction as a foundational rationale for targeted anti‐cancer therapy: promises and perils
Torti, D., & Trusolino, L. (2011) · EMBO Molecular Medicine · doi:10.1002/emmm.201100176 · Cited by 246
Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer
Cejalvo, J. M., Martínez de Dueñas, E., Galván, P., García-Recio, S., Burgués Gasión, O., Paré, L., Antolín, S., Martinello, R., Blancas, I., Adamo, B., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2717 · Cited by 245
Partridge, A. H., Rumble, R. B., Carey, L. A., Come, S. E., Davidson, N. E., Di Leo, A., Gralow, J., Hortobagyi, G. N., Moy, B., Yee, D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.7479 · Cited by 240
Wang, Y.-Q., Wang, P.-Y., Wang, Y.-T., Yang, G.-F., Zhang, A., & Miao, Z.-H. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00055 · Cited by 235
Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry
Brewster, A. M., Chavez-MacGregor, M., & Brown, P. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70364-x · Cited by 235
Recent therapeutic trends and promising targets in triple negative breast cancer
Hwang, S.-Y., Park, S., & Kwon, Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.006 · Cited by 232
PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials
Dey, N., De, P., & Leyland-Jones, B. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.037 · Cited by 229
Siddharth, S., & Sharma, D. (2018) · Cancers · doi:10.3390/cancers10120514 · Cited by 224
Drug Resistance and the Role of Combination Chemotherapy in Improving Patient Outcomes
Yardley, D. A. (2013) · International Journal of Breast Cancer · doi:10.1155/2013/137414 · Cited by 216
Basal-Like and Triple-Negative Breast Cancers
Alluri, P. G., & Newman, L. A. (2014) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2014.03.003 · Cited by 215
Failure of Iniparib to Inhibit Poly(ADP-Ribose) Polymerase In Vitro
Patel, A. G., De Lorenzo, S. B., Flatten, K. S., Poirier, G. G., & Kaufmann, S. H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2890 · Cited by 212
Emerging targeted therapies in triple-negative breast cancer
Crown, J., O'Shaughnessy, J., & Gullo, G. (2012) · Annals of Oncology · doi:10.1093/annonc/mds196 · Cited by 208
Self-citationLalloo, F., & Evans, D. G. (2012) · Clinical Genetics · doi:10.1111/j.1399-0004.2012.01859.x · Cited by 202
Targeting DNA Repair Pathways for Cancer Treatment: what’s new?
Kelley, M. R., Logsdon, D., & Fishel, M. L. (2014) · Future Oncology · doi:10.2217/fon.14.60 · Cited by 202
Glucocorticoid Receptor Antagonism as a Novel Therapy for Triple-Negative Breast Cancer
Skor, M. N., Wonder, E. L., Kocherginsky, M., Goyal, A., Hall, B. A., Cai, Y., & Conzen, S. D. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3826 · Cited by 201
Synthetic lethality: exploiting the addiction of cancer to DNA repair
Shaheen, M., Allen, C., Nickoloff, J. A., & Hromas, R. (2011) · Blood · doi:10.1182/blood-2011-01-313734 · Cited by 198
Therapeutic targeting of tumor suppressor genes
Morris, L. G. T., & Chan, T. A. (2015) · Cancer · doi:10.1002/cncr.29140 · Cited by 197
Brain metastases: pathobiology and emerging targeted therapies
Preusser, M., Capper, D., Ilhan-Mutlu, A., Berghoff, A. S., Birner, P., Bartsch, R., Marosi, C., Zielinski, C., Mehta, M. P., Winkler, F., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-011-0933-9 · Cited by 197
A Review of Systemic Treatment in Metastatic Triple-Negative Breast Cancer
Zeichner, S. B., Terawaki, H., & Gogineni, K. (2016) · Breast Cancer: Basic and Clinical Research · doi:10.4137/bcbcr.s32783 · Cited by 196
Combination Drug Delivery Approaches in Metastatic Breast Cancer
Lee, J. H., & Nan, A. (2012) · Journal of Drug Delivery · doi:10.1155/2012/915375 · Cited by 192
ICAM-1 as a molecular target for triple negative breast cancer
Guo, P., Huang, J., Wang, L., Jia, D., Yang, J., Dillon, D. A., Zurakowski, D., Mao, H., Moses, M. A., & Auguste, D. T. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1408556111 · Cited by 192
Management of patients with metastatic breast cancer
Jurado, J. C., Aznar, P. R., Mata, J. G., Martínez, R. F., Fernández, I. P., Gimeno, T. S., Calvo, E. G., Jaso, L. M., Marqués, E. P., & Palomo, A. G. (2011) · Advances in Therapy · doi:10.1007/s12325-011-0046-9 · Cited by 192
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations
Dedes, K. J., Wilkerson, P. M., Wetterskog, D., Weigelt, B., Ashworth, A., & Reis-Filho, J. S. (2011) · Cell Cycle · doi:10.4161/cc.10.8.15273 · Cited by 191
Jones, P., Wilcoxen, K., Rowley, M., & Toniatti, C. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm5018237 · Cited by 183
Structural Implications for Selective Targeting of PARPs
Steffen, J. D., Brody, J. R., Armen, R. S., & Pascal, J. M. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00301 · Cited by 182
Rojo, F., García-Parra, J., Zazo, S., Tusquets, I., Ferrer-Lozano, J., Menendez, S., Eroles, P., Chamizo, C., Servitja, S., Ramírez-Merino, N., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr361 · Cited by 181
PARP inhibitors: its role in treatment of cancer
Chen, A. (2011) · Chinese Journal of Cancer · doi:10.5732/cjc.011.10111 · Cited by 179
Drew, Y., Zenke, F. T., & Curtin, N. J. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01060-w · Cited by 178
DNA Damage Repair Pathways in Cancer Stem Cells
Maugeri-Saccà, M., Bartucci, M., & De Maria, R. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-1040 · Cited by 178
Treating Breast Cancer in the 21st Century: Emerging Biological Therapies
Tinoco, G., Warsch, S., Glück, S., Avancha, K., & Montero, A. J. (2013) · Journal of Cancer · doi:10.7150/jca.4925 · Cited by 176
Induction of apoptosis in MDA-MB-231 breast cancer cells by a PARP1-targeting PROTAC small molecule
Zhao, Q., Lan, T., Su, S., & Rao, Y. (2019) · Chemical Communications · doi:10.1039/c8cc07813k · Cited by 176
Triple-Negative Breast Cancer and the Need for New Therapeutic Targets
Engebraaten, O., Vollan, H. K. M., & Børresen-Dale, A.-L. (2013) · The American Journal of Pathology · doi:10.1016/j.ajpath.2013.05.033 · Cited by 175
Liu, X., Shi, Y., Maag, D. X., Palma, J. P., Patterson, M. J., Ellis, P. A., Surber, B. W., Ready, D. B., Soni, N. B., Ladror, U. S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1973 · Cited by 174
Targeting triple-negative breast cancer: optimising therapeutic outcomes
Gelmon, K., Dent, R., Mackey, J. R., Laing, K., McLeod, D., & Verma, S. (2012) · Annals of Oncology · doi:10.1093/annonc/mds067 · Cited by 171
Targeted Therapy for Breast Cancer
Mohamed, A., Krajewski, K., Çakar, B., & Ma, C. X. (2013) · American Journal Of Pathology · doi:10.1016/j.ajpath.2013.07.005 · Cited by 171
Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET
Basilico, C., Pennacchietti, S., Vigna, E., Chiriaco, C., Arena, S., Bardelli, A., Valdembri, D., Serini, G., & Michieli, P. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3459 · Cited by 169
Triple-Negative Breast Carcinoma
Schmadeka, R., Harmon, B. E., & Singh, M. (2014) · American Journal of Clinical Pathology · doi:10.1309/ajcpqn8gz8silkgn · Cited by 167
Molecularly targeted therapies for metastatic triple-negative breast cancer
Bayraktar, S., & Glück, S. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2421-5 · Cited by 165
Zumsteg, Z. S., Morrow, M., Arnold, B. B., Zheng, J., Zhang, Z., Robson, M. E., Traina, T. A., McCormick, B. L., Powell, S. N., & Ho, A. Y. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3011-9 · Cited by 165
Pathway inhibition: emerging molecular targets for treating glioblastoma
Wick, W., Weller, M., Weiler, M., Batchelor, T. T., Yung, A. W. K., & Platten, M. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor039 · Cited by 165
A Phase I Combination Study of Olaparib with Cisplatin and Gemcitabine in Adults with Solid Tumors
Rajan, A., Carter, C. A., Kelly, R. J., Gutierrez, M., Kummar, S., Szabo, E., Yancey, M. A., Ji, J., Mannargudi, B., Woo, S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2425 · Cited by 164
Hereditary Breast Cancer: Clinical, Pathological and Molecular Characteristics
Larsen, M. J., Thomassen, M., Gerdes, A., & Kruse, T. A. (2014) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s18715 · Cited by 162
The role of DNA repair pathways in cisplatin resistant lung cancer
O’Grady, S., Finn, S. P., Cuffe, S. D., Richard, D. J., O'Byrne, K. J., & Barr, M. P. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.10.003 · Cited by 161
Triple-negative breast cancer: new perspectives for targeted therapies
Tomao, F., Tomao, F., Rossi, L., Zaccarelli, E., Caruso, D., Minozzi, M., Frati, L., Papa, A., & Vici (2015) · OncoTargets and Therapy · doi:10.2147/ott.s67673 · Cited by 160
Met as a therapeutic target in HCC: Facts and hopes
Giordano, S., & Columbano, A. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.09.009 · Cited by 158
Samol, J., Ranson, M., Scott, E., Macpherson, E., Carmichael, J., Thomas, A., & Cassidy, J. (2012) · Investigational New Drugs · doi:10.1007/s10637-011-9682-9 · Cited by 158
DNA Repair: From Genome Maintenance to Biomarker and Therapeutic Target
Jalal, S. I., Earley, J. N., & Turchi, J. J. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0761 · Cited by 156
Alba, E., Chacón, J. I., Lluch, A. M., Anton, A., Estevez, L., Cirauqui, B., Carrasco, E., Calvo, L., Seguí, M. Á., Ribelles, N., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2100-y · Cited by 155
Therapeutic targets in triple negative breast cancer
O'Toole, S. A., Beith, J. M., Millar, E. K. A., West, R. H., McLean, A. E. B., Cazet, A., Swarbrick, A., & Oakes, S. R. (2013) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2012-201361 · Cited by 154
Yan, Q., Xu, R., Zhu, L., Cheng, X., Wang, Z., Manis, J. P., & Shipp, M. A. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00990-12 · Cited by 153
The prognostic value of tumour-stroma ratio in triple-negative breast cancer
Moorman, A. M., Vink, R., Heijmans, H. J., van der Palen, J. A. M., & Kouwenhoven, E. A. (2012) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2012.01.002 · Cited by 153
Effect of ASCO/CAP guidelines for determining ER status on molecular subtype
Deyarmin, B., Kane, J. L., Valente, A. L., van Laar, R., Gallagher, C., Shriver, C. D., & Ellsworth, R. E. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2588-8 · Cited by 149
Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014
Morgensztern, D., Campo, M. J., Dahlberg, S. E., Doebele, R. C., Garon, E. B., Gerber, D. E., Goldberg, S. B., Hammerman, P. S., Heist, R. S., Hensing, T. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000405 · Cited by 149
Inhibition of poly(ADP-ribosyl)ation in cancer: Old and new paradigms revisited
Lupo, B., & Trusolino, L. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.07.004 · Cited by 148
Triple Negative Breast Cancer: A Brief Review of its Characteristics and Treatment Options
Griffiths, C. L., & Olin, J. L. (2012) · Journal of Pharmacy Practice · doi:10.1177/0897190012442062 · Cited by 147
Harbeck, N., Scharl, A. J., Thomssen, C., & Müller, V. (2013) · Breast Care · doi:10.1159/000353590 · Cited by 147
Liu, Y., Zhu, Y., Mao, C., Dou, S., Shen, S., Tan, Z., & Wang, J. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.07.001 · Cited by 146
Metastatic Triple-negative Breast Cancer
Rakha, E. A., & Chan, S. Y. T. (2011) · Clinical Oncology · doi:10.1016/j.clon.2011.03.013 · Cited by 144
Brufsky, A., Valero, V., Tiangco, B., Dakhil, S. R., Brize, A., Rugo, H. S., Rivera, R., Duenne, A., Bousfoul, N., & Yardley, D. A. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2008-6 · Cited by 143
Calcium Channel TRPV6 as a Potential Therapeutic Target in Estrogen Receptor–Negative Breast Cancer
Peters, A. A., Simpson, P. T., Bassett, J. J., Lee, J. M., Silva, L. M. D., Reid, L., Song, S., Parat, M., Lakhani, S. R., Kenny, P. A., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0965 · Cited by 141
Yardley, D. A., Coleman, R., Conte, P., Cortés, J., Brufsky, A., Shtivelband, M. I., Young, R. R., Bengala, C., Ali, H. Y., Eakel, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy201 · Cited by 140
Self-citationWilliamson, C. T., Kubota, E., Hamill, J. D., Klimowicz, A. C., Ye, R., Muzik, H., Dean, M. L., Tu, L., Gilley, D. P., Magliocco, A. M., et al. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201200229 · Cited by 139
Metadata
- Authors
- O'Shaughnessy, J., Osborne, C., Pippen, J. E., Yoffe, M., Patt, D., Rocha, C., Koo, I. C., Sherman, B. M., & Bradley, C.
- Affiliations
- Texas Oncology (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2011-01-20
- Volume
- 364
- Issue
- 3
- Pages
- 205-214
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2111429259
- Cited by
- 817
- References
- 32
- Citations by year
- 2026: 3 · 2025: 11 · 2024: 6 · 2023: 22 · 2022: 23 · 2021: 30 · 2020: 27 · 2019: 30 · 2018: 47 · 2017: 52 · 2016: 42 · 2015: 72 · 2014: 90 · 2013: 94 · 2012: 133
- FWCI
- 70.91
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- metastatic triple-negative breast cancer, PARP inhibition, gemcitabine, carboplatin, combination chemotherapy, DNA repair deficiency, clinical benefit, progression-free survival, overall survival, adverse events, neutropenia, thrombocytopenia, drug safety and efficacy
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Gemcitabine, Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Benzamides, Breast Neoplasms, Deoxycytidine, Female, Humans, Neoplasm Metastasis, Survival Analysis, Carboplatin, Cross-Over Studies, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.